XML 48 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended 60 Months Ended 114 Months Ended
Jan. 31, 2019
Feb. 28, 2017
Mar. 31, 2015
Jun. 30, 2010
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2019
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Revenues         $ 244,010,000 $ 222,094,000 $ 183,580,000 $ 138,403,000 $ 131,492,000 $ 151,757,000 $ 96,905,000 $ 71,086,000 $ 788,087,000 $ 451,240,000 $ 161,626,000    
Acquired in-process research and development                         154,272,000 4,750,000 30,000,000    
Restricted investment in equity securities fair value amount         55,868,000               55,868,000     $ 55,868,000 $ 55,868,000
Development and Regulatory Milestone Payments                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Potential milestone payments         4,900,000,000               4,900,000,000     4,900,000,000 4,900,000,000
AbbVie                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payments received       $ 75,000,000.0                          
Revenues                           40,000,000.0 30,000,000.0    
Patent rights period       ten years or the life of the related patent rights.                          
Collaborative arrangement right description       We will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.                          
Collaboration termination notice period       180 days                          
AbbVie | Royalty                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Revenues                         14,300,000 1,600,000      
AbbVie | Regulatory and Clinical Results and FDA Acceptance Milestones                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Revenues                         20,000,000.0        
AbbVie | Topic 606                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payments received       $ 75,000,000.0                          
AbbVie | Development and Regulatory Milestone Payments                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Potential development and regulatory milestone payment receipts       480,000,000.0                          
Revenues                                 135,000,000.0
AbbVie | Commercial Milestone Payments                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Potential commercial milestone payment receipts       $ 50,000,000.0                          
B I A L                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Acquired in-process research and development   $ 30,000,000.0                              
B I A L | Parkinson's Disease                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Potential payments for regulatory milestones         20,000,000.0               20,000,000.0     20,000,000.0 20,000,000.0
B I A L | Event Based Milestones                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Payments made for regulatory milestones         10,000,000.0               10,000,000.0     10,000,000.0 10,000,000.0
B I A L | R&D Expense and FDA Acceptance Milestones                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Payments made for regulatory milestones             10,000,000.0                    
B I A L | Regulatory Approval and Net Sales Milestones                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Potential milestone payments   $ 95,000,000.0                              
Voyager Therapeutics | Collaboration and License Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Collaboration termination notice period 180 days                                
Upfront payments made $ 115,000,000.0                                
Restricted investment in equity securities cost $ 50,000,000.0                                
Share price $ 11.9625                                
Restricted investment in equity securities fair value amount $ 54,700,000                                
Voyager Therapeutics | Collaboration and License Agreement | IPR&D                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Acquired in-process research and development             $ 5,000,000.0 $ 113,100,000                  
Voyager Therapeutics | Collaboration and License Agreement | Common Stock                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Restricted investment in equity securities number of shares 4.2                                
Voyager Therapeutics | Collaboration and License Agreement | Development, Regulatory and Commercial Milestone Payment                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Potential milestone payments $ 1,700,000,000                                
Xenon | Collaboration and License Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payments made         30,000,000.0               30,000,000.0     30,000,000.0 30,000,000.0
Restricted investment in equity securities cost         $ 20,000,000.0               $ 20,000,000.0     $ 20,000,000.0 $ 20,000,000.0
Share price         $ 14.196               $ 14.196     $ 14.196 $ 14.196
Restricted investment in equity securities fair value amount         $ 14,100,000               $ 14,100,000     $ 14,100,000 $ 14,100,000
Xenon | Collaboration and License Agreement | IPR&D                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Acquired in-process research and development         $ 36,200,000                        
Xenon | Collaboration and License Agreement | Common Stock                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Restricted investment in equity securities number of shares         1.4               1.4     1.4 1.4
Xenon | Collaboration and License Agreement | Development, Regulatory and Commercial Milestone Payment                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Potential milestone payments         $ 1,700,000,000               $ 1,700,000,000     $ 1,700,000,000 $ 1,700,000,000
Mitsubishi Tanabe                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payments received     $ 30,000,000.0                            
Revenues                             $ 15,000,000.0    
Patent rights period     the longer of ten years or the life of the related patent rights.                            
Collaborative arrangement right description     Under the terms of the agreement, MTPC is responsible for all third-party development, marketing and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to us. We do not directly control when event-based payments will be achieved or when royalty payments will begin. MTPC may terminate the agreement at its discretion upon 180 days’ written notice to us. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to us.                            
Collaboration termination notice period     180 days                            
Potential milestone payment receipts     $ 85,000,000.0                            
Revenues recognized under collaboration agreement                           $ 0   20,600,000  
Deferred revenue recognized                         900,000        
Up-front license fees     $ 30,000,000.0                            
Deferred revenues         $ 9,400,000               $ 9,400,000     $ 9,400,000 $ 9,400,000